CMPX 1.85 Compass Therapeutics, Inc.
| Range: | 0.765-2.34 | Vol Avg: | 462768 | Last Div: | 0 | Changes: | -0.05 |
| Beta: | 0.73 | Cap: | 0.26B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Apr 05 2021 | Empoloyees: | 32 | ||
| CUSIP: | 20454B104 | CIK: | 0001738021 | ISIN: | US20454B1044 | Country: | US |
| CEO: | Dr. Thomas J. Schuetz M.D., Ph.D. | Website: | https://www.compasstherapeutics.com | ||||
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Stock Details
CMPX 5
Ladenburg Thalmann Upgrades Compass Therapeutics (CMPX) to Buy
Aydin Huseynov·Mon Sep 16 2024
Compass Point
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow